GET DAILY SIGNALSGlaukos Corporation (GKOS) Climbs +14.4% Over 30 Days on Product Momentum
Key Takeaways
- Glaukos Corporation (GKOS) shares rose roughly 14.4% over the trailing 30 days, climbing from about $158.56 on September 28, 2026, to $181.47 by October 28, 2026.
- The advance extends a broader rally, with the stock up approximately 19.9% over the trailing three months.
- Momentum is anchored by the iDose TR glaucoma implant and the launch of Epioxa, the first FDA-approved epithelium-on corneal cross-linking therapy for keratoconus.
- Second-quarter 2026 results showed record net sales of $185.6 million, up 50% year over year, prompting management to raise full-year revenue guidance.
- Trading has been volatile, including a sharp early-October pullback after Epioxa Phase 3 extension data, before shares recovered toward multi-year highs.
- Key risks include proposed Medicare local coverage determinations for iDose TR and ongoing reimbursement and competitive pressures.
- Explore additional data on Glaukos' Price Targets, Earnings, and Forecast to support your research.
- You can also track automated strategies in the curated Trending AI Robots section.
Company Overview: Glaukos (GKOS) and Its Position in Ophthalmology
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on novel therapies for glaucoma, corneal disorders, and retinal diseases. Headquartered in Aliso Viejo, California, the company has built a leadership position in micro-invasive glaucoma surgery (MIGS) through products such as iStent, iStent inject, iStent infinite, and the PRESERFLO MicroShunt. Its flagship growth driver is iDose TR, a sustained-release travoprost implant designed to lower intraocular pressure in patients with glaucoma or ocular hypertension, while its corneal health franchise is anchored by Photrexa and the newly launched Epioxa. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow the stock closely because of its expanding commercial infrastructure, differentiated technology platforms, and a pipeline spanning glaucoma, corneal health, and retinal disease.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Glaukos shares advanced approximately 14.4%, rising from a closing price of $158.56 on September 28, 2026, to $181.47 by October 28, 2026. The move was not a straight line: shares dipped near $153 in late September, rallied toward $172 in early October, pulled back sharply on October 8 following the Epioxa Phase 3 extension data announcement, and then recovered into the high $170s and low $180s ahead of the company's third-quarter report. The longer-term trend is even stronger. Over the trailing quarter, the stock climbed roughly 19.9%, from about $151.33 in late July to $181.47, driven primarily by a well-received second-quarter earnings report and a series of raised revenue forecasts. The shares have traded near the upper end of a wide 52-week range that spans from a low near $76.88 to a high of $191.62.
What Drove the Recent 30-Day Advance
The recent advance reflects continued investor confidence in Glaukos' two transformational growth engines. iDose TR generated approximately $74 million in sales during the second quarter, and management has highlighted growing surgeon adoption, increasing utilization, and expanding payer access. The Epioxa launch has also progressed, with a product-specific J-code (J2789) effective July 1, 2026, and market-access pathways established for more than 125 million covered commercial lives in the U.S. The 30-day window also included a notable bout of volatility. In early October, Glaukos announced positive three-year Phase 3 extension data for Epioxa demonstrating sustained effectiveness and safety; despite the favorable data, the stock fell more than 13% in a single session as investors weighed valuation and launch-related expectations. Shares subsequently rebounded as analysts reiterated a broadly bullish stance on the stock and as momentum building toward the third-quarter report outweighed near-term concerns.
Quarterly Performance Drivers and Earnings Results
The quarterly gain of roughly 19.9% is anchored by Glaukos' second-quarter 2026 results, reported on July 29. The company posted record consolidated net sales of $185.6 million, up 50% year over year, and an adjusted loss of $0.14 per share that was narrower than consensus expectations. U.S. glaucoma revenue rose 64% to a record $118.5 million, while corneal health revenue climbed 48% to $30.4 million, including approximately $11 million from Epioxa. Management raised its full-year 2026 net sales guidance to a range of $680 million to $700 million, up from $620 million to $635 million previously. The combination of accelerating revenue, improving gross margins, and narrowing operating losses reinforced the narrative that Glaukos is transitioning toward sustained growth and eventual profitability, supporting the stock's multi-month uptrend.
Key Factors to Watch Going Forward
Several factors are likely to shape Glaukos' trajectory in the months ahead. The pace of iDose TR adoption and utilization remains the central growth driver, along with the continued commercial ramp of Epioxa and the expansion of its site-of-care network. Reimbursement developments also carry weight: five of the seven Medicare administrative contractors have issued proposed local coverage determinations for iDose TR, and the final outcomes could influence near-term volume trends. Investors will also monitor guidance updates, gross-margin trajectory, and progress toward narrowing operating losses as the company scales. Competitive dynamics in MIGS globally, foreign-exchange effects, and broader macroeconomic conditions affecting elective ophthalmic procedures round out the list of variables to watch. As with any growth-stage medical technology company, execution on launch milestones and payer access will be critical to sustaining the recent momentum.
Using AI Tools to Track Trading Strategies
In my research process, I often review Tickeron’s Trending AI Robots to get a curated view of automated strategies across hundreds of tickers. The platform highlights top-performing bots with varying timeframes and risk profiles, which can offer useful perspective on how systematic approaches are positioned relative to manual analysis. This helps round out my own assessment without replacing core fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GKOS's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for GKOS moved out of oversold territory on September 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 18 similar instances when the indicator left oversold territory. In 16 of the 18 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 05, 2026. You may want to consider a long position or call options on GKOS as a result. In 79 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for GKOS just turned positive on October 02, 2026. Looking at past instances where GKOS's MACD turned positive, the stock continued to rise in 48 of 58 cases over the following month. The odds of a continued upward trend are 83%.
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +5.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GKOS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.658) is normal, around the industry mean (3.837). P/E Ratio (-55.404) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an ophthalmic medical device company
Industry MedicalNursingServices
Advertisement